The latest price target for Cogent Biosciences (NASDAQ:COGT) was reported by Needham on June 27, 2024. The analyst firm set a price target for $18.00 expecting COGT to rise to within 12 months (a possible 109.06% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Cogent Biosciences (NASDAQ:COGT) was provided by Needham, and Cogent Biosciences reiterated their buy rating.

There is no last upgrade for Cogent Biosciences

The last downgrade for Cogent Biosciences Inc happened on February 26, 2024 when Baird changed their price target from $14 to $8 for Cogent Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cogent Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cogent Biosciences was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.

While ratings are subjective and will change, the latest Cogent Biosciences (COGT) rating was a reiterated with a price target of $18.00 to $18.00. The current price Cogent Biosciences (COGT) is trading at is $8.61, which is out of the analyst’s predicted range.